LSUHSC research describes function of key protein in cancer spreadMay 22, 2009New Orleans, LA - Research led by David Worthylake, PhD, Assistant Professor of Biochemistry and Molecular Biology at LSU Health Sciences Center New Orleans, may help lay the groundwork for the development of a compound to prevent the spread of cancer. The research will be published in the May 29, 2009 issue of the Journal of Biological Chemistry. During the transition from a localized tumor to metastatic disease, cancer cells acquire the ability to detach from their neighboring cells and move to and invade tissue at distant points in the body. "Because tumor metastasis leads to a poor prognosis and tremendously complicates treatment, it is of utmost importance that we understand, at a molecular level, the processes that regulate cell adhesion, migration and invasion," notes Dr. Worthylake. He and his colleagues studied a protein in cells that is involved in regulating cell structure, cell-to-cell contact, and cell movement. When too much of this protein, called IQGAP1, is produced, it can weaken cell-to-cell contacts and promote cell migration and invasion - processes that occur during tumor metastasis. The research team focused on the area of IQGAP1 that interacts with two smaller proteins Cdc42 and Rac which, when activated, contribute to cell destabilization, cell movement, and invasion. This region on IQGAP1 is related to proteins that accelerate deactivation of another small protein similar to Cdc42 and Rac. However, IQGAP1 does not deactivate Cdc42 and Rac - in fact, IQGAP1 prolongs their activated states. The researchers determined the atomic structure of this region of IQGAP1 and furthermore, built a model of their IQGAP1 structure bound to the previously determined structure of Cdc42 in order to understand why IQGAP1 does not deactivate Cdc42. The model provides detailed information about the (likely) specific contacts made between IQGAP1 and Cdc42. The model also shows that IQGAP1 is missing a key component required to rapidly deactivate Cdc42, and that binding to IQGAP1 likely disturbs the positions of components of Cdc42 that are required for even normal rates of deactivation, explaining how IQGAP1 prolongs the activated state of Cdc42. "This knowledge could serve as a guide for further studies to define IQGAP1 function and perhaps the design of a small molecule to regulate Cdc42/IQGAP1 interaction to prevent cancer cells from moving to and invading other parts of the body," concludes Dr. Worthylake. According to the American Cancer Society, metastatic cancer is a cancer that has spread from its primary site (the part of the body in which it developed) to other parts of the body. If cells break away from a cancerous tumor, they can travel to other areas of the body. There, they may settle and form "colony" tumors. In their new location, the cancer cells continue growing. The spread of a tumor to a new part of the body is called metastasis. Most people who die of cancer have metastases at the time of their death, and metastatic disease is directly responsible for the majority of cancer deaths. This year, about 562,340 Americans are expected to die ofcancer, more than 1,500 people a day. Cancer is the second most common cause of death in the US, exceeded only by heart disease. In the US, cancer accounts for nearly 1 of every 4 deaths. Louisiana State University Health Sciences Center |
|||||||||||||||||||||
| Related Cancer Spread Current Events and Cancer Spread News Articles Radiation therapy technique successfully treats pain in patients with advanced cancer Stereotactic radiosurgery (SRS), a radiation therapy procedure pioneered at the University of Pittsburgh Cancer Institute (UPCI) that precisely delivers a large dose of radiation to tumors, effectively controls pain in patients with cancer that has spread to the spine. Radiation costs vary widely by delivery, U-M study finds When cancer spreads to the bone, radiation treatments can help relieve the pain caused by the tumor. But how best to deliver the radiation may vary widely from one oncologist to the next. Mayo Clinic Researchers Find That Protein Believed to Protect Against Cancer Has a Mr. Hyde Side In a biological rendition of fiction's Strange Case of Dr. Jekyll and Mr. Hyde, researchers from the Mayo Clinic campus in Florida and Harvard Medical School have found that a protein thought to protect against cancer development can actually spur the spread of tumors. Survival predictors may help customize treatment options for men with metastatic prostate cancer Four risk factors that help predict how long men may survive with metastatic prostate cancer could help doctors choose more effective treatments, according to a study led by researchers in the Duke Comprehensive Cancer Center. Autopsy Study Links Prostate Cancer to Singe Rogue Cell One cell"¦one initial set of genetic changes -- that's all it takes to begin a series of events that lead to metastatic cancer. Brain metastases hijack neuron-supporting cells to resist chemotherapy Cancer that spreads to other organs finds a particularly inviting hideout in the brain, where these metastases are usually far harder to treat than they are in other locations. Scorpion venom with nanoparticles slows spread of brain cancer By combining nanoparticles with a scorpion venom compound already being investigated for treating brain cancer, University of Washington researchers found they could cut the spread of cancerous cells by 98 percent, compared to 45 percent for the scorpion venom alone. Pregnancy has no impact on breast cancer, but can delay diagnosis and treatment A new study finds women who develop breast cancer while pregnant or soon afterwards do not experience any differences in disease severity or likelihood of survival compared to other women with breast cancer. Molecular imaging enables earlier, individualized treatment of thyroid cancer In a study to determine the diagnostic value of molecular imaging in nodal staging of patients with thyroid cancer, researchers were able for the first time to accurately distinguish between cancerous cells in regional lymph nodes and normal residual thyroid tissue directly after surgery. Targeted radiation therapy can control limited cancer spread Precisely targeted radiation therapy can eradicate all evidence of disease in selected patients with cancer that has spread to only a few sites, suggests the first published report from an ongoing clinical trial. More Cancer Spread Current Events and Cancer Spread News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||